Intratumoral Cancer Therapy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Company Analysis
Intratumoral Cancer Therapy Market Outlook
Global Intratumoral Cancer Therapy Market will reach US$ 212.92 Billion by 2027. As per Globocan statistics Worldwide, cancer is the highest cause of death; with 19,292,789 new cancer cases were diagnosed and around 9,958,133 cancer death happened in the year 2020. Nevertheless, over the past years, the treatment paradigm of cancer has transformed with several therapies such as radiation therapies, chemotherapies, and immunotherapies available to treat cancer. Correspondingly, intratumoral immunotherapy is a cancer treatment that improves the immune system's ability to fight cancer. This therapy is preferable to the old technique because it provides long-term cancer protection, has fewer side effects, and treats a broader range of cancer.
Impact of COVID-19 on Intratumoral Cancer Therapy Industry:
COVID-19 had a mixed impact on the intratumoral cancer therapy industry. Due to the lockdown restrictions and travel ban, it was difficult for the patients to get the therapy done. In the COVID- 19, there is a high chance for cancer patients to get infected because COVID 19 affects the patient's immune systems. However, continuous cancer intratumoral treatment processes for cancer patients are mandatory, and it enhances their immune system's ability to fight against COVID. Intratumoral therapy is a cancer treatment that boosts the human immune system to fight against cancer cells. Further, cancer patients require regular monitoring of the conditions, resulting in industry growth.
Although many factors propel the growth of the global intratumoral cancer therapy market, such as an increase in healthcare expenditure, a surge in access to medical insurance, a rise in the incidence of cancer, and a rise in technological advancements in cancer treatment therapies. According to Renub Research report, the Worldwide Intratumoral Cancer Therapy Market Size was US$ 111.41 Billion in 2021.
Global Intratumoral Cancer Therapy Industry will grow at a CAGR of 11.4% from 2021-2027
Based on technology, the intratumoral cancer therapy industry includes Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others. The monoclonal antibody technology has the most significant growth in the previous year, owing to a surge in monoclonal antibodies for cancer immunotherapy. They exhibit different properties where the immune technique can be modulated, and thus they can activate or inhibit the molecules targeted on the immune system. Additionally, monoclonal antibodies also generate the antitumor immune response. There are various monoclonal antibodies, such as naked, conjugated, and bispecific monoclonal antibodies.
In terms of application, cancer intratumoral therapy is used to treat various cancer applications like Colorectal Cancer, Melanoma, Prostate Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, and others. Lungs cancer had the most consequential market. Owing to the high incidence of lung cancer globally and the surge in the awareness program regarding the need for early lung cancer therapeutics. The U.S. food and drug administration has authorized Tabrecta (Capmatinib) to regale non-small cell lung cancer in 2020.
North America holds a Considerable Cancer Intratumoral Therapy Market Worldwide
Geographically, North America held a considerable global cancer intratumoral therapy market. Rising accessibility to current therapy and increasing cancer disease incidence, combined with a growing senior population, lead to regional market development. Recently, U.S. food and administration has supported 32 various immunotherapies to treat 20 cancer diseases, including immunomodulators, cell-based immunotherapies, BCG vaccines, targeted therapies, and oncotic viruses.
The Asia Pacific is to experience the fastest growth owing to a rise in healthcare expenditure, the surge in per capita income, and improvement in healthcare infrastructure. Countries like China and Japan are introducing new and sophisticated immunotherapy medications. These countries have clinical trials for new drug molecules, alternative treatments, and FDA approval.
Key Market Players:
The major players operating in the global intratumoral cancer therapy market include Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc.
Renub Research report titled “Intratumoral Cancer Therapy Market, Global Forecast, by Application (Colorectal Cancer, Melanoma, Prostate Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, and others), Technology Type (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others), End Users (Hospital, Cancer Research Centres, Clinical), Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc)” provides a complete analysis of Global Intratumoral Cancer Therapy Industry
Application - Market has been covered from 7 viewpoints
1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Melanoma
5. Prostate Cancer
6. Head & Neck Cancer
7. Others
Technology Type - Market has been covered from 6 viewpoints
1. Monoclonal Antibodies
2. Vaccines
3. Checkpoint Inhibitors
4. Cell Therapies
5. Immune System Modulators
6. Adoptive Cell Transfer
7. Cytokines
8. Others
End Users - Market has been covered from 3 viewpoints
1. Hospital
2. Cancer Research Centres
3. Clinical
Regions - Market has been covered from 5 viewpoints
1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East & Africa
Company Insights:
• Overview
• Initiatives & Strategy
• Revenue
Companies Covered in the Report:
1. Amgen Inc
2. AstraZeneca
3. Bayer AG
4. Bristol-Myers Squibb Company
5. Pfizer Inc
6. Novarts AG
7. Johnson & Johnson
8. Eli Lily Company
9. F. Hoffmann-la Roche Ltd
10. Seattle Genetics Inc
Report Details:
| Report Features | Details |
| Base Year | 2021 |
| Historical Period | 2016 - 2021 |
| Forecast Period | 2022 - 2027 |
| Market | US$ Billion |
| Segment Covered | Application, Technology Type, End Users, Regions |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Frequently Asked Questions
• What is global intratumoral cancer therapies used for?
• What would be forecast period of global intratumoral cancer therapies market?
• What would be market value of global intratumoral cancer therapies market in future?
• What are the essential trends in the global intratumoral cancer therapies market?
• Which segment holds the maximum market share of the global intratumoral cancer therapies market?
• What are the key industry players opinions for the global intratumoral cancer therapies market?
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Drivers
4.2 Restraints
5. Global Intratumoral Cancer Therapy Market
6. Market Share Analysis - Global Intratumoral Cancer Therapy Market
6.1 By Application
6.2 Technology Type
6.3 By End User
6.4 By Regions
7. Application - Global Intratumoral Cancer Therapy Market
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Colorectal Cancer
7.4 Melanoma
7.5 Prostate Cancer
7.6 Head & Neck Cancer
7.7 Others
8. Technology Type - Global Intratumoral Cancer Therapy Market
8.1 Monoclonal Antibodies
8.2 Vaccines
8.3 Checkpoint Inhibitors
8.4 Cell Therapies
8.5 Immune System Modulators
8.6 Adoptive Cell Transfer
8.7 Cytokines
8.8 Others
9. End Users - Global Intratumoral Cancer Therapy Market
9.1 Hospital
9.2 Cancer Research Centres
9.3 Clinica
10. Regions - Global Intratumoral Cancer Therapy Market
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Latin America
10.5 Middle East & Africa
11. Porters Five Forces
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12. Company Analysis – Global Intratumoral Cancer Therapy Market
12.1 Amgen Inc.
12.1.1 Overview
12.1.2 Initiatives & Strategy
12.1.3 Revenue
12.2 AstraZeneca
12.2.1 Overview
12.2.2 Initiatives & Strategy
12.2.3 Revenue
12.3 Bayer AG
12.3.1 Overview
12.3.2 Initiatives & Strategy
12.3.3 Revenue
12.4 Bristol-Myers Squibb Comapny
12.4.1 Overview
12.4.2 Initiatives & Strategy
12.4.3 Revenue
12.5 Pfizer Inc
12.5.1 Overview
12.5.2 Initiatives & Strategy
12.5.3 Revenue
12.6 Novarts AG
12.6.1 Overview
12.6.2 Initiatives & Strategy
12.6.3 Revenue
12.7 Johnson & Johnson
12.7.1 Overview
12.7.2 Initiatives & Strategy
12.7.3 Revenue
12.8 Eli Lily Comapny
12.8.1 Overview
12.8.2 Initiatives & Strategy
12.8.3 Revenue
12.9 F. Hoffmann-la Roche Ltd
12.9.1 Overview
12.9.2 Initiatives & Strategy
12.9.3 Revenue
12.10 Seattle Genetics Inc
12.10.1 Overview
12.10.2 Initiatives & Strategy
12.10.3 Revenue
List Of Figures:
Figure-01: Global – Intratumoral Cancer Therapy Market (Billion US$), 2017 – 2021
Figure-02: Global – Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 – 2027
Figure-03: Application – Lung Cancer Market (Billion US$), 2017 – 2021
Figure-04: Application – Forecast for Lung Cancer Market (Billion US$), 2022 – 2027
Figure-05: Application – Breast Cancer Market (Billion US$), 2017 – 2021
Figure-06: Application – Forecast for Breast Cancer Market (Billion US$), 2022 – 2027
Figure-07: Application – Colorectal Cancer Market (Billion US$), 2017 – 2021
Figure-08: Application – Forecast for Colorectal Cancer Market (Billion US$), 2022 – 2027
Figure-09: Application – Melanoma Market (Billion US$), 2017 – 2021
Figure-10: Application – Forecast for Melanoma Market (Billion US$), 2022 – 2027
Figure-11: Application – Prostate Cancer Market (Billion US$), 2017 – 2021
Figure-12: Application – Forecast for Prostate Cancer Market (Billion US$), 2022 – 2027
Figure-13: Application – Head & Neck Cancer Market (Billion US$), 2017 – 2021
Figure-14: Application – Forecast for Head & Neck Cancer Market (Billion US$), 2022 – 2027
Figure-15: Application – Others Market (Billion US$), 2017 – 2021
Figure-16: Application – Forecast for Others Market (Billion US$), 2022 – 2027
Figure-17: Technology Type – Monoclonal Antibodies Market (Billion US$), 2017 – 2021
Figure-18: Technology Type – Forecast for Monoclonal Antibodies Market (Billion US$), 2022 – 2027
Figure-19: Technology Type – Vaccines Market (Billion US$), 2017 – 2021
Figure-20: Technology Type – Forecast for Vaccines Market (Billion US$), 2022 – 2027
Figure-21: Technology Type – Checkpoint Inhibitors Market (Billion US$), 2017 – 2021
Figure-22: Technology Type – Forecast for Checkpoint Inhibitors Market (Billion US$), 2022 – 2027
Figure-23: Technology Type – Cell Therapies Market (Billion US$), 2017 – 2021
Figure-24: Technology Type – Forecast for Cell Therapies Market (Billion US$), 2022 – 2027
Figure-25: Technology Type – Immune System Modulators Market (Billion US$), 2017 – 2021
Figure-26: Technology Type – Forecast for Immune System Modulators Market (Billion US$), 2022 – 2027
Figure-27: Technology Type – Adoptive Cell Transfer Market (Billion US$), 2017 – 2021
Figure-28: Technology Type – Forecast for Adoptive Cell Transfer Market (Billion US$), 2022 – 2027
Figure-29: Technology Type – Cytokines Market (Billion US$), 2017 – 2021
Figure-30: Technology Type – Forecast for Cytokines Market (Billion US$), 2022 – 2027
Figure-31: Technology Type – Others Market (Billion US$), 2017 – 2021
Figure-32: Technology Type – Forecast for Others Market (Billion US$), 2022 – 2027
Figure-33: End User – Hospital Market (Billion US$), 2017 – 2021
Figure-34: End User – Forecast for Hospital Market (Billion US$), 2022 – 2027
Figure-35: End User – Cancer Research Centres Market (Billion US$), 2017 – 2021
Figure-36: End User – Forecast for Cancer Research Centres Market (Billion US$), 2022 – 2027
Figure-37: End User – Clinical Market (Million US$), 2017 – 2021
Figure-38: End User – Forecast for Clinical Market (Million US$), 2022 – 2027
Figure-39: North America – Intratumoral Cancer Therapy Market (Billion US$), 2017 – 2021
Figure-40: North America – Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 – 2027
Figure-41: Europe – Intratumoral Cancer Therapy Market (Million US$), 2017 – 2021
Figure-42: Europe – Forecast for Intratumoral Cancer Therapy Market (Million US$), 2022 – 2027
Figure-43: Asia Pacific – Intratumoral Cancer Therapy Market (Billion US$), 2017 – 2021
Figure-44: Asia Pacific – Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 – 2027
Figure-45: Latin America – Intratumoral Cancer Therapy Market (Billion US$), 2017 – 2021
Figure-46: Latin America – Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 – 2027
Figure-47: Middle East & Africa – Intratumoral Cancer Therapy Market (Million US$), 2017 – 2021
Figure-48: Middle East & Africa – Forecast for Intratumoral Cancer Therapy Market (Million US$), 2022 – 2027
Figure-49: Amgen Inc. – Global Revenue (Million US$), 2017 – 2021
Figure-50: Amgen Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-51: AstraZeneca – Global Revenue (Million US$), 2017 – 2021
Figure-52: AstraZeneca – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-53: Bayer AG – Global Revenue (Million US$), 2017 – 2021
Figure-54: Bayer AG – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-55: Bristol-Myers Squibb Comapny – Global Revenue (Million US$), 2017 – 2021
Figure-56: Bristol-Myers Squibb Comapny – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-57: Pfizer Inc – Global Revenue (Million US$), 2017 – 2021
Figure-58: Pfizer Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-59: Novarts AG – Global Revenue (Million US$), 2017 – 2021
Figure-60: Novarts AG – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-61: Johnson & Johnson – Global Revenue (Million US$), 2017 – 2021
Figure-62: Johnson & Johnson – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-63: Eli Lily Comapny – Global Revenue (Million US$), 2017 – 2021
Figure-64: Eli Lily Comapny – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-65: F. Hoffmann-la Roche Ltd – Global Revenue (Million US$), 2017 – 2021
Figure-66: F. Hoffmann-la Roche Ltd – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-67: Seattle Genetics Inc – Global Revenue (Million US$), 2017 – 2021
Figure-68: Seattle Genetics Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
List Of Tables:
Table-01: Global – Intratumoral Cancer Therapy Market Share by Application (Percent), 2017 – 2021
Table-02: Global – Forecast for Intratumoral Cancer Therapy Market Share by Application (Percent), 2022 – 2027
Table-03: Global – Intratumoral Cancer Therapy Market Share by Technology Type (Percent), 2017 – 2021
Table-04: Global – Forecast for Intratumoral Cancer Therapy Market Share by Technology Type (Percent), 2022 – 2027
Table-05: Global – Intratumoral Cancer Therapy Market Share by End User (Percent), 2017 – 2021
Table-06: Global – Forecast for Intratumoral Cancer Therapy Market Share by End User (Percent), 2022 – 2027
Table-07: Global – Intratumoral Cancer Therapy Market Share by Region (Percent), 2017 – 2021
Table-08: Global – Forecast for Intratumoral Cancer Therapy Market Share by Region (Percent), 2022 – 2027
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com